Abstract: A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, which gives rise to opportunities for the development of further active agents and screening methods.
Type:
Grant
Filed:
June 9, 2015
Date of Patent:
November 8, 2016
Assignee:
HAMLET PHARMA AB
Inventors:
Catharina Svanborg, Kenneth Hun Mok, Maria Trulsson, Ann-Kristin Mossberg, Petter Storm, Ching Shing Ho
Abstract: The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
Type:
Grant
Filed:
June 7, 2012
Date of Patent:
November 8, 2016
Assignee:
Hanmi Science Co., Ltd.
Inventors:
Sung Youb Jung, Myung Hyun Jang, Ling Ai Shen, Young Kyung Park, Young Jin Park, Se Chang Kwon
Abstract: This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity.
Abstract: The present invention relates to a composition for maintaining efficacy of a filler for a long period of time by containing collagen as an active ingredient. The composition according to the present invention is useful since the composition can promote the synthesis of hyaluronic acid and inhibit activity of hyaluronidase, thereby maintaining the efficacy of a hyaluronic acid filler for a longer period of time. Therefore, even with less number of times of filler injection, the efficacy of the filler can be maintained and skin irritation can be also reduced.
Type:
Grant
Filed:
February 27, 2014
Date of Patent:
October 25, 2016
Assignee:
AMOREPACIFIC CORPORATION
Inventors:
Hyun Jung Shin, Jin Kyu Choi, Byung Gyu Kim, Dae Bang Seo, Sang Jun Lee
Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.
Type:
Grant
Filed:
August 26, 2015
Date of Patent:
October 25, 2016
Assignee:
Novo Nordisk A/S
Inventors:
Ulrich Sensfuss, Thomas Kruse, Jesper F. Lau
Abstract: The present invention provides a novel ?-conotoxin peptide, pharmaceutical composition and use thereof. The present invention further provides a propeptide of the conotoxin peptide, a nucleic acid construct, expression vector and transformed cell of the conotoxin peptide as well as a fused protein of the conotoxin peptide. The present invention discloses a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The ?-conotoxin peptide of the present invention can specifically block acetylcholine receptor (nAChRs, such as ?3?2 nAChRs, ?6/?3?2?3 nAChR or ?3?4 nAChR or ?6/?3?4 nAChR), has activity for treatment of neuralgia, addiction, Parkinson's disease, dementia, schizophrenia, cancers, and can be used in the manufacture of a medicament for analgesia and smoking cessation and drug-withdrawal, a medicament for treatment of mental diseases and cancers, as well as a tool drug for neurosciences.
Type:
Grant
Filed:
June 18, 2013
Date of Patent:
October 18, 2016
Assignee:
HAINAN UNIVERSITY
Inventors:
Sulan Luo, Dongting Zhangsun, Yong Wu, Xiaopeng Zhu, Yuanyan Hu, Hui Bing, J. Michael McIntosh
Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
October 4, 2016
Assignee:
SANOFI-AVENTIS DEUTSCHLAND GMBH
Inventors:
Harald Rau, Felix Cleemann, Ulrich Hersel, Silvia Kaden-Vagt, Torben Lessmann, Thomas Wegge
Abstract: Provided is niacin-peptide which has skin whitening activity. The peptide of the present invention has skin whitening activity by inhibiting melanogenesis, that is, by inhibiting the expression of a gene related to melanogenesis (for example, TRP-1, TRP2, or MIFT). The peptide of the present invention has high stability and skin permeability. Also provided is a cosmetic composition for skin whitening which contains the niacin-peptide.
Abstract: A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis. Specifically, said series of integrin blockers include polypeptide I, polypeptide II and polypeptide III (see SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3) that can be adopted in treatment of solid tumors and rheumatoid arthritis. This invention also relates to application of these three integrin-blocking polypeptides in preparation of anti-tumor drugs, wherein the tumors that can be treated include those primary or secondary cancers originated from head and neck region or other organs such as brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gallbladder, colon, rectum, ovary, cervix, uterus, prostate, bladder and testicle, as well as melanoma and sarcomas.
Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
Type:
Grant
Filed:
October 8, 2015
Date of Patent:
September 27, 2016
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
Abstract: Provided herein are methods for increasing insulin sensitivity in a subject. A method may comprise administering to a subject in need of increased insulin sensitivity a therapeutically effective amount of a glypican-4 agent. Also provided herein are methods for determining whether a subject is or is likely to become insulin resistant. A method may comprise determining the level of glypican-4 in a subject, wherein an elevated level of glypican-4 indicates that a subject is or is likely to become insulin resistant.
Abstract: Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer.
Type:
Grant
Filed:
October 7, 2009
Date of Patent:
September 6, 2016
Assignees:
REXAHN PHARMACEUTICALS, INC., University of Maryland, Baltimore
Inventors:
Young B. Lee, Deog J. Kim, Chang H. Ahn, Anjan Nan, Hamidreza Ghandehari, Abhijit Ray
Abstract: A vaccine and method of vaccination for conferring immunity to Q fever is described. The vaccine comprises a polypeptide with a sequence of SLTWHKHELHRK (SEQ ID NO: 7) (m1E41920) or SPPWHKHELHRK (SEQ ID NO: 8) (m1E44), or at least 90% identity to m1E41920 or m1E44. Constructs are also provided for use in vaccination and treatment of Q fever. A method to identify and generate new vaccines to prevent diseases caused by intracellular Gram-negative bacteria is also described.
Type:
Grant
Filed:
July 23, 2014
Date of Patent:
August 23, 2016
Assignee:
The Curators of the University of Missouri
Abstract: The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.
Abstract: A composition including an artificially synthesized antimicrobial peptide that is not present as a mature peptide in nature. The composition includes an artificially synthesized peptide that has an antimicrobial activity against at least one strain of bacteria or fungi and includes an amino acid sequence represented by any one of SEQ ID NOs: 1 to 6 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the amino acid sequence, and further including at least one species of pharmaceutically acceptable carrier.
Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
Type:
Grant
Filed:
November 9, 2015
Date of Patent:
June 21, 2016
Assignee:
NOVO NORDISK HEALTHCARE AG
Inventors:
Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen, Carsten Behrens, Paul L. DeAngelis, Friedrich Michael Haller
Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
Type:
Grant
Filed:
October 15, 2014
Date of Patent:
June 21, 2016
Assignee:
NOVO NORDISK HEALTHCARE AG
Inventors:
Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen